SEC Form 4 · accession 0001127602-18-029875
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laura Hamill
Officer — EVP, Worldwide Commercial Ops
Period of report
Oct 7, 2018
Accepted (ET)
Oct 9, 2018 · 7:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F1 | $76.24 | Oct 7, 2018 | A | 87,680 | A | — | Oct 7, 2028 | Common Stock | 87,680 | 87,680 | D |
| Restricted Stock UnitF2,F3 | — | Oct 7, 2018 | A | 32,795 | A | — | — | Common Stock | 32,795 | 32,795 | D |
Explanation of responses
- F1The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
- F2Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- F3The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.